Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;28(9):5166-5182.
doi: 10.1245/s10434-021-09887-y. Epub 2021 Jul 5.

Development and Psychometric Validation of a Patient-Reported Outcome Measure for Arm Lymphedema: The LYMPH-Q Upper Extremity Module

Anne F Klassen  1 , Elena Tsangaris  2 , Manraj N Kaur  2 , Lotte Poulsen  3   4   5 , Louise M Beelen  2 , Amalie Lind Jacobsen  3   4   5 , Mads Gustaf Jørgensen  3   4 , Jens Ahm Sørensen  3   4 , Dalibor Vasilic  6 , Joseph Dayan  7 , Babak Mehrara  7 , Andrea L Pusic  2
Affiliations

Development and Psychometric Validation of a Patient-Reported Outcome Measure for Arm Lymphedema: The LYMPH-Q Upper Extremity Module

Anne F Klassen et al. Ann Surg Oncol. 2021 Sep.

Abstract

Background: A multiphased mixed-methods study was performed to develop and validate a comprehensive patient-reported outcome measure (PROM) for arm lymphedema in women with breast cancer (i.e., the LYMPH-Q Upper Extremity Module).

Methods: Qualitative interviews (January 2017 and June 2018) were performed with 15 women to elicit concepts specific to arm lymphedema after breast cancer treatment. Data were audio-recorded, transcribed, and coded. Scales were refined through cognitive interviews (October and Decemeber 2018) with 16 patients and input from 12 clinical experts. The scales were field-tested (October 2019 and January 2020) with an international sample of 3222 women in the United States and Denmark. Rasch measurement theory (RMT) analysis was used to examine reliability and validity.

Results: The qualitative phase resulted in six independently functioning scales that measure arm symptoms, function, appearance, psychological function, and satisfaction with information and with arm sleeves. In the RMT analysis, all items in each scale had ordered thresholds and nonsignificant chi-square p values. For all the scales, the reliability statistics with and without extremes for the Person Separation Index were 0.80 or higher, Cronbach's alpha was 0.89 or higher, and the Intraclass Correlation Coefficients were 0.92 or higher. Lower (worse) scores on the LYMPH-Q Upper Extremity scales were associated with reporting of more severe arm swelling, an arm problem caused by cancer and/or its treatment, and wearing of an arm sleeve in the past 12 months.

Conclusions: The LYMPH-Q Upper Extremity Module can be used to measure outcomes that matter to women with upper extremity lymphedema. This new PROM was designed using a modern psychometric approach and, as such, can be used in research and in clinical care.

PubMed Disclaimer

Conflict of interest statement

The LYMPH-Q Upper Extremity Module is owned by Memorial Sloan-Kettering Cancer Center, McMaster University, and Mass General Brigham, and Pusic and Klassen are co-developers. The remaining authors have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Mean scores for LYMPH-Q scales based on self-reported severity of arm swelling
Fig. 2
Fig. 2
Mean scores for LYMPH-Q scales based on having a problem with the arm(s) as a result of breast cancer and/or its treatment
Fig. 3
Fig. 3
Mean scores for LYMPH-Q scales based on whether the participant wore a compression sleeve in the past 12 months
None
Threshold maps and person-item threshold distributions for each LYMPH-Q Upper Extremity scale from the RMT analysis
See this image and copyright information in PMC

References

    1. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500–515. doi: 10.1016/S1470-2045(13)70076-7. - DOI - PubMed
    1. McDuff SGR, Mina AI, Brunelle CL, et al. Timing of lymphedema after treatment for breast cancer: when are patients most at risk? Int J Radiat Oncol Biol Phys. 2019;103:62–70. doi: 10.1016/j.ijrobp.2018.08.036. - DOI - PMC - PubMed
    1. Pereira ACPR, Koifman RJ, Bergmann A. Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast. 2017;36:67–73. doi: 10.1016/j.breast.2017.09.006. - DOI - PubMed
    1. Taghian NR, Miller CL, Jammallo LS, et al. Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol. 2014;92:227–234. doi: 10.1016/j.critrevonc.2014.06.004. - DOI - PubMed
    1. Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. 2013;7:83–92. doi: 10.1007/s11764-012-0247-5. - DOI - PMC - PubMed